Franks PW, Hanson RL, Knowler WC, Sievers ML, Bennett PH, Looker HC. Childhood obesity, other cardiovascular risk factors and premature death. N Engl J Med 2010; 362:485–493.
 Morandi A, Maffeis C. Predictors of metabolic risk in childhood obesity. Hormone research in paediatrics 2014; 82(1): 3-11.
 Faienza M F, Wang D Q H, Frühbeck G, et al. The dangerous link between childhood and adulthood predictors of obesity and metabolic syndrome. Internal and emergency medicine 2016; 11(2): 175-182.
Gallagher EJ, LeRoith D, Karnieli E. The metabolic syndrome-from insulin resistance to obesity and diabetes. Endocrinol Metab Clin North Am 2008;37:559–579.
Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ. GLP‐1 and energy balance: an integrated model of short‐term and long‐term control. Nat Rev Endocrinol 2011; 7: 507– 516.
Field BC, Chaudhri OB, Bloom SR. Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol 2010; 6: 444- 453.
Kumar KG, Trevaskis JL, Lam DD et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008; 8: 468– 481.
Celik A, Balin M, Kobat MA, Erdem K, Baydas A, et al. Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc Ther 2013;31:174–8.
Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 1998; 251, 471–476.
Dray C, Knauf C, Daviaud D, et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell metabolism 2008; 8(5): 437-445.
Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2006;114:544-8.
Carpe ne C, Dray C, Attane C, Valet P, Portillo MP, Churruca I, Milagro FI, and Castan-Laurell I. Expanding role for the apelin/APJ system in physiopathology. J. Physiol. Biochem. 2007; 63, 359–373.
Castan-Laurell I, Vitkova M, Daviaud D, Dray D, Kovacikova M, Kovacova Z, Hejnova J, Stich V, and Valet, P. Effect of hypocaloricinduced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur. J. Endocrinol. 2008;158, 905–910.
Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005;146:1764-71.
Mi J, Wang T, Meng LH, Zhu GJ, Han SM, Zhong Y et al. Development of blood pressure reference standards for Chinese children. Chin J Evid Based Pediatr 2010;5: 4-14
Liang, L., Fu, J.F. & Du, J.B. Significance of exploring the definition of metabolic syndrome in chinese children and adolescents. Chinese Journal of Pediatrics 2012; 50: 401–404.
Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, Fan L. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clinical Chemistry and Laboratory Medicine 2014; 52, 751-758.
Yosaee S, Khodadost M, Esteghamati A, et al. Metabolic syndrome patients have lower levels of adropin when compared with healthy overweight/obese and lean subjects. American journal of men's health, 2017, 11(2): 426-434.
Karbek B, Bozkurt N C, Topaloglu O, et al. Relationship of vaspin and apelin levels with insulin resistance and atherosclerosis in metabolic syndrome. Minerva Endocrinol 2014; 39(2): 99-105.
Heinonen M V, Laaksonen D E, Karhu T, et al. Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutrition, Metabolism and Cardiovascular Diseases 2009; 19(9): 626-633.
Asayama K, Hayashibe H, Dobashi K, et al. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obesity research 2003; 11(9): 1072-1079.
Perseghin G, Lattuada G, De Cobelli F, et al. Serum retinol-binding protein-4, leptin, and adiponectin concentrations are related to ectopic fat accumulation. The Journal of Clinical Endocrinology & Metabolism 2007; 92(12): 4883-4888.
Ganesh‐Kumar K, Zhang J, Gao S, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity 2012;20(7): 1394-1402.
Niepolski L, Grzegorzewska A E. Salusins and adropin: new peptides potentially involved in lipid metabolism and atherosclerosis. Advances in medical sciences 2016; 61(2): 282-287.
Franks P W, Brage S, Luan J A, et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obesity Research 2005;13(8): 1476-1484.
Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circulation journal 2004; 68(11): 975-981.